From: Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
Line of targeted therapy
PFS in months (range)
All
Sun
Sor
Eve
Tem
Other
1st
2.4
PR
(1-4.6)
SD
PD
35
28
7
2nd
3.2
(1-16.6)
10
1
4
3
2
15
8
3rd
1.9
(1-15)
9
6
4th
2.6
(1-9)